Results 111 to 120 of about 40,821 (327)

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure [PDF]

, 2017
Aims: It is unclear whether distinct pathophysiological processes are present among patients with acute heart failure (AHF), with and without diabetes.
Bloomfield, Daniel M., Cleland, John G.F., Cotter, Gad, Davison, Beth A., Demissei, Biniyam G., Dittrich, Howard, Ezekowitz, Justin A., Givertz, Michael M., Hillege, Hans L., Khan, Mohsin A.F., Metra, Marco, O'Connor, Christopher M., Ponikowski, Piotr, Sharma, Abhinav, Teerlink, John R., Tromp, Jasper, van Veldhuisen, Dirk J., Voors, Adriaan A.   +17 more
core   +2 more sources

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis

Frontiers in Pharmacology
IntroductionEndothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ETA receptor antagonists has been limited due to associated fluid retention.
K. Melissa Hallow, K. Melissa Hallow, Peter J. Greasley, Hiddo J. L. Heerspink, Hiddo J. L. Heerspink, Hongtao Yu   +5 more
doaj   +1 more source

Supplementary Figure 3 from Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice

, 2023
Sun-Jin Kim, Ho Jeong Lee, Mark Seungwook Kim, Hyun Jin Choi, Junqin He, Qiuyu Wu, Kenneth Aldape, Jeffrey S. Weinberg, W.K. Alfred Yung, Charles A. Conrad, Robert R. Langley, François Lehembre, Urs Regenass, Isaiah J. Fidler   +13 more
openalex   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

The use of Macitentan in Fontan circulation: a case report

BMC Cardiovascular Disorders, 2017
Background The Fontan circulation, a result of a palliative procedure in patients with single systemic ventricles, is defined by chronically elevated pulmonary vascular resistance.
Polyvios Demetriades, Amir Aziz, Robin Condliffe, Sarah E. Bowater, Paul F. Clift   +4 more
doaj   +1 more source

Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats [PDF]

, 2004
Waldemar Urbanowicz, P Sogni, R Moreau, K A Tazi, E Barriere, O Poirel, A Martin, M C Guimont, D Cazals-Hatem, D Lebrec   +9 more
openalex   +1 more source

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, EarlyView.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Current status of bosentan for treatment of pulmonary hypertension

Annals of Cardiac Anaesthesia, 2008
Pulmonary arterial hypertension (PAH) is a debilitating disease associated with significant morbidity and a high mortality if left untreated. Over the past 5 years, there have been significant advances with regard to the understanding of the pathogenesis,
Raja Shahzad, Dreyfus Gilles
doaj  

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art

Frontiers in Pediatrics, 2019
Idiopathic pulmonary arterial hypertension (IPAH) is a complex disease associated with progressive deterioration. Targeted therapy for IPAH has improved in the last several decades.
Yuchen Wang, Yuchen Wang, Selena Chen, Junbao Du, Junbao Du   +4 more
doaj   +1 more source